Hutchmed (China) announced today that it has launched a phase I clinical trial of HMPL-506 for the treatment of hematologic malignancies in China. The first patient received initial treatment on May 31, 2024.

This study is a multicenter, open-label phase I clinical trial designed to evaluate the safety, pharmacokinetics, and efficacy of HMPL-506 in the treatment of hematologic malignancies. The study will be conducted in two stages, including dose escalation and dose expansion, with plans to enroll at least 60 patients. The primary investigators are Dr. Jianxiang Wang and Dr. Hui Wei from the Hematology Hospital, Chinese Academy of Medical Sciences.